BioPharma Dive February 14, 2025
Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public in a challenging market for biotech stocks.
Drug development is a notoriously expensive business. Discovering, testing and advancing a medicine can cost hundreds of millions of dollars, putting immense pressure on young biotechnology companies to be on constant lookout for new sources of funding.
For such a cash-hungry industry, initial public offerings act as lifelines. Shares bought by big banks and institutional investors like mutual funds provide the money needed to keep research afloat and get new therapies to patients.
Over the last several years, though, a major downturn in the biotech stock market has made going public much harder...
Today's Sponsors
Today's Sponsor